Compare Okta, Inc. (OKTA) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs Tango Therapeutics Inc. — how do they compare? Okta, Inc. trades at $206.01 (market cap $37.05B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Okta, Inc. is far larger — about 9.9× Tango Therapeutics Inc.'s market cap, and Okta, Inc. is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Okta, Inc. for 44 Days and Tango Therapeutics Inc. for 0 Days on average.
| OKTA | TNGX | |
|---|---|---|
Market Cap | $37.05B | $3.74B |
Volume | 4,638,855 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $232.13 | $32.90 |
52-Week Low | $62.93 | $7.50 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $34.80B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $226.53, showing modest daily weakness with a 0.24% decline. The stock maintains strong bullish technical momentum with consistent earnings beats and positive analyst sentiment. Recent developments include the company's AI Agent Security Blueprint Alliance announcement at Oktane 2026, positioning Okta for growth in the emerging AI security market. Fundamental improvements show revenue growth from $2.3B in 2024 to $2.6B in 2025, with the company achieving profitability after several years of losses.
Outlook remains positive with 74% analyst buy ratings and a $245 high price target, though valuation multiples appear stretched with P/E of 136. Key risks include competitive pressures in cybersecurity and the stock's premium valuation. The transition to profitability and AI security positioning provide catalysts, but investors should monitor execution against growth expectations.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
